Apple Opens iPhone to Alternative App Stores in Japan Under New Competition Law 
Republicans Raise National Security Concerns Over Intel’s Testing of China-Linked Chipmaking Tools 
Delta Air Lines President Glen Hauenstein to Retire, Leaving Legacy of Premium Strategy 
Blackstone Leads $400 Million Funding Round in Cyera at $9 Billion Valuation 
TikTok U.S. Deal Advances as ByteDance Signs Binding Joint Venture Agreement 
Union-Aligned Investors Question Amazon, Walmart and Alphabet on Trump Immigration Policies 
Volaris and Viva Agree to Merge, Creating Mexico’s Largest Low-Cost Airline Group 
Treasury Wine Estates Shares Plunge on Earnings Warning Amid U.S. and China Weakness 
FDA Fast-Tracks Approval of Altria’s on! PLUS Nicotine Pouches Under New Pilot Program 
Oracle Stock Surges After Hours on TikTok Deal Optimism and OpenAI Fundraising Buzz 
Robinhood Expands Sports Event Contracts With Player Performance Wagers 
OpenAI Explores Massive Funding Round at $750 Billion Valuation 
Harris Associates Open to Revised Paramount Skydance Bid for Warner Bros Discovery 
FedEx Beats Q2 Earnings Expectations, Raises Full-Year Outlook Despite Stock Dip 
Toyota to Sell U.S.-Made Camry, Highlander, and Tundra in Japan From 2026 to Ease Trade Tensions 
Trump Administration Reviews Nvidia H200 Chip Sales to China, Marking Major Shift in U.S. AI Export Policy 
Boeing Seeks FAA Emissions Waiver to Continue 777F Freighter Sales Amid Strong Cargo Demand 
MALAKOFF, France, Aug. 22, 2017 -- THERACLION (Alternext, FR0010120402 - ALTHE), a company specialized in leading-edge medical equipment for echotherapy, today announced that it will host a conference call and webcast to discuss the recently FDA-authorized clinical trial combining the checkpoint inhibitor, pembrolizumab, with Theraclion’s echotherapy (also known as High Intensity Focused Ultrasound, HIFU) in women with metastatic breast cancer. David Brenin, M.D., a co-lead investigator of the trial will describe the clinical trial.
Event: Theraclion Echotherapy + Immuno-Oncology Combination Clinical Trial
Date: Thursday, September 7, 2017
Time: 11 a.m. EDT
The dial-in numbers for the call are +1-877-718-5107 (United States) and +1-719-325-4917 (International). The conference ID number is 9476148. A live webcast of the conference call will be available on the investor relations page of the Theraclion corporate website at www.theraclion.com. The webcast will also be archived for one year on the investor relations page of the company’s website.
David Brenin, M.D., FACS, is chief of breast surgery, co-director of both the University of Virginia (UVA) Breast Care Program and the High-Risk Breast and Ovarian Cancer Clinic and is an associate professor of surgery at UVA’s School of Medicine. His clinical practice specializes in the treatment of breast cancer, and benign diseases of the breast. Dr. Brenin is a fellowship trained breast surgeon and is an expert on surgical procedures involving the breast including lumpectomy, sentinel node biopsy, axillary dissection, nipple sparing mastectomy and IORT. His primary research interests include focused ultrasound ablation of breast tumors and immunotherapy.
About Theraclion
Theraclion is a French company specializing in high-tech medical equipment using therapeutic ultrasound. Drawing on leading-edge technologies, Theraclion has designed and manufactured an innovative solution for echotherapy, the Echopulse®, allowing non-invasive tumor treatment through ultrasound-guided high-intensity focused ultrasound. Theraclion is ISO 13485 certified and has received the CE mark for non-invasive ablation of breast fibroadenomas and thyroid nodules. Based in Malakoff, near Paris, France Theraclion has brought together a team of 34 people, 50% of whom are dedicated to R&D and clinical trials. For more information, please visit Theraclion’s website: www.theraclion.com.
Theraclion is listed on Alternext Paris
PEA-PME Eligible
Mnemonic: ALTHE - ISIN Code: FR0010120402
Contacts: Theraclion David Caumartin CEO Tel.: +33 (0)1 55 48 90 70 [email protected] Kalima Press Relations Florence Calba Tel.: + 33 (0)1 44 90 82 54 [email protected] The Ruth Group (U.S.) Investor Relations / Public Relations Robert Flamm / Kirsten Thomas +1 646-536-7017 / +1 508-280-6592 [email protected] / [email protected]
